PTCT - PTC Therapeutics Inc logo

PTC Therapeutics Inc

PTCT

PTC Therapeutics develops and commercializes medicines for rare disorders, offering treatments such as Translarna for Duchenne muscular dystrophy and Evrysdi for spinal muscular atrophy. Its pipeline includes gene therapies and small molecules for various conditions.

⚕️ Healthcare NASDAQ Listed 2013 $ USD
$1,000 invested 10 years ago →$9,123today

Score Overview

1 Year
Score
Net Growth-105.62%
Net TrendShrank
Net Income Consistency—
Rev Growth-41.71%
Rev TrendShrank
Revenue Consistency—
5 Years
Score5.3
Net Growth92.67%
Net Trend40%
Net Income Consistency—
Rev Growth87.29%
Rev Trend60%
Revenue Consistency—
10 Years
Score
Net Growth72.99%
Net Trend30%
Net Income Consistency
Rev Growth12x
Rev Trend80%
Revenue Consistency
All Time
Score
Net Growth25.58%
Net Trend31%
Net Income Consistency
Rev Growth32x
Rev Trend77%
Revenue Consistency

Explore the 2021 public Archive ranking →

Where PTC Therapeutics Inc has ranked, year by year

Measure
Fundamentals Window

Not enough ranking history to display a chart

This chart needs at least two years of available HDB Score rankings on 10 years of fundamentals. PTCT does not have enough ranked years in the public Archive through 2021.

More recent Archive years are available with Membership. Coverage varies by company and measure.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-10-22
$ 63.04—
1 Year2025-10-22
$ 66.52-5.23%
5 Years2021-10-22
$ 35.9975.16%
10 Years2016-10-21
$ 6.919x
All Time2013-06-20
$ 16.49282.29%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

Year
TTM$ 1.00B-$ 38M$ 2.22B
2025$ 1.73B$ 682M$ 1.94B
2024$ 806M-$ 363M$ 1.13B
2023$ 937M-$ 626M$ 876M
2022$ 698M-$ 559M$ 410M
2021$ 538M-$ 523M$ 773M
2020$ 380M-$ 438M$ 1.10B
2019$ 306M-$ 251M$ 686M
2018$ 264M-$ 128M$ 227M
2017$ 194M-$ 79M$ 191M
2016$ 82M-$ 142M$ 231M
2015$ 36M-$ 170M$ 338M
2014$ 22M-$ 93M$ 315M
IPO2013$ 31M-$ 51M$ 142M
PTCT - PTC Therapeutics Inc logo

PTC Therapeutics Inc fundamental performance

Between 2020 and 2025, revenue grew from $ 380M to $ 1.73B and net income went from -$ 438M to $ 682M. Revenue increased in 3 of those 5 years; net income in 2.

Between 2015 and 2025, revenue grew from $ 36M to $ 1.73B and net income went from -$ 170M to $ 682M. Revenue increased in 8 of those 10 years; net income in 3.

PTC Therapeutics Inc currently holds a 5-year HDB Score of 5.3 out of 10. How the HDB Score is calculated.

Membership

Explore PTCT with current data

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 5,119 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year · Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies